E7080

DRUG5 trials

Sponsors

Eisai Inc., Eisai Co., Ltd.

Conditions

CancerCancer: Solid TumorsMetastatic MelanomaNon-small-cell Lung CancerSolid Tumors

Phase 1

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

CompletedNCT00121680

Eisai Inc.Metastatic Melanoma

Start: 2005-07-31End: 2015-05-31Updated: 2015-12-11

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

CompletedNCT00280397

Eisai Inc.Cancer: Solid Tumors

Start: 2006-01-31End: 2008-11-30Updated: 2016-10-07

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

CompletedNCT00832819

Eisai Co., Ltd.Non-small-cell Lung Cancer

Start: 2009-02-28End: 2011-10-31Updated: 2015-04-30

A Study of E7080 in Subjects With Solid Tumor

CompletedNCT01268293

Eisai Co., Ltd.Cancer

Start: 2011-02-28End: 2013-04-30Updated: 2023-06-22

Phase 2

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

CompletedNCT03477175

Eisai Inc.Solid Tumors

Start: 2018-08-16End: 2023-12-21Updated: 2025-01-07

Related Papers

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

BMC Cancer2014-07-2140 citations

Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.

2013-05-1426 citations